Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Molecular concepts analysis links tumors, pathways, mechanisms, and drugs.

Rhodes DR, Kalyana-Sundaram S, Tomlins SA, Mahavisno V, Kasper N, Varambally R, Barrette TR, Ghosh D, Varambally S, Chinnaiyan AM.

Neoplasia. 2007 May;9(5):443-54.

2.

Identifying regulatory mechanisms underlying tumorigenesis using locus expression signature analysis.

Lee E, de Ridder J, Kool J, Wessels LF, Bussemaker HJ.

Proc Natl Acad Sci U S A. 2014 Apr 15;111(15):5747-52. doi: 10.1073/pnas.1309293111. Epub 2014 Apr 2.

3.

Laser microdissection and microarray analysis of breast tumors reveal ER-alpha related genes and pathways.

Yang F, Foekens JA, Yu J, Sieuwerts AM, Timmermans M, Klijn JG, Atkins D, Wang Y, Jiang Y.

Oncogene. 2006 Mar 2;25(9):1413-9.

PMID:
16261164
4.

Topological network analysis of differentially expressed genes in cancer cells with acquired gefitinib resistance.

Lee YS, Hwang SG, Kim JK, Park TH, Kim YR, Myeong HS, Kwon K, Jang CS, Noh YH, Kim SY.

Cancer Genomics Proteomics. 2015 May-Jun;12(3):153-66.

PMID:
25977174
5.

Estrogen and growth factor signaling pathway: basic approaches for clinical application.

Hayashi S, Sakamoto T, Inoue A, Yoshida N, Omoto Y, Yamaguchi Y.

J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):433-42.

PMID:
14623541
6.

Pathway analysis of cancer-associated microRNA targets.

Yang H, Zhang H, Zhu L, Wang J, Zhang C, Li D.

Int J Oncol. 2012 Dec;41(6):2213-26. doi: 10.3892/ijo.2012.1658. Epub 2012 Oct 11.

PMID:
23064433
7.

Network modeling links breast cancer susceptibility and centrosome dysfunction.

Pujana MA, Han JD, Starita LM, Stevens KN, Tewari M, Ahn JS, Rennert G, Moreno V, Kirchhoff T, Gold B, Assmann V, Elshamy WM, Rual JF, Levine D, Rozek LS, Gelman RS, Gunsalus KC, Greenberg RA, Sobhian B, Bertin N, Venkatesan K, Ayivi-Guedehoussou N, Solé X, Hernández P, Lázaro C, Nathanson KL, Weber BL, Cusick ME, Hill DE, Offit K, Livingston DM, Gruber SB, Parvin JD, Vidal M.

Nat Genet. 2007 Nov;39(11):1338-49. Epub 2007 Oct 7.

PMID:
17922014
8.

An integrative multi-dimensional genetic and epigenetic strategy to identify aberrant genes and pathways in cancer.

Chari R, Coe BP, Vucic EA, Lockwood WW, Lam WL.

BMC Syst Biol. 2010 May 17;4:67. doi: 10.1186/1752-0509-4-67.

9.

Correlation signature of the macroscopic states of the gene regulatory network in cancer.

Slavov N, Dawson KA.

Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4079-84. doi: 10.1073/pnas.0810803106. Epub 2009 Feb 25.

10.

Gene expression analysis in clear cell renal cell carcinoma using gene set enrichment analysis for biostatistical management.

Maruschke M, Reuter D, Koczan D, Hakenberg OW, Thiesen HJ.

BJU Int. 2011 Jul;108(2 Pt 2):E29-35. doi: 10.1111/j.1464-410X.2010.09794.x. Epub 2011 Mar 16.

11.

Coexpression network analysis identifies transcriptional modules related to proastrocytic differentiation and sprouty signaling in glioma.

Ivliev AE, 't Hoen PA, Sergeeva MG.

Cancer Res. 2010 Dec 15;70(24):10060-70. doi: 10.1158/0008-5472.CAN-10-2465.

12.

Network-based Identification of novel cancer genes.

Ostlund G, Lindskog M, Sonnhammer EL.

Mol Cell Proteomics. 2010 Apr;9(4):648-55. doi: 10.1074/mcp.M900227-MCP200. Epub 2009 Dec 3.

13.

Meta-analysis of breast cancer microarray studies in conjunction with conserved cis-elements suggest patterns for coordinate regulation.

Smith DD, Saetrom P, Snøve O Jr, Lundberg C, Rivas GE, Glackin C, Larson GP.

BMC Bioinformatics. 2008 Jan 28;9:63. doi: 10.1186/1471-2105-9-63.

14.

Pathway analysis of gene signatures predicting metastasis of node-negative primary breast cancer.

Yu JX, Sieuwerts AM, Zhang Y, Martens JW, Smid M, Klijn JG, Wang Y, Foekens JA.

BMC Cancer. 2007 Sep 25;7:182.

15.

Mining for regulatory programs in the cancer transcriptome.

Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Barrette TR, Ghosh D, Chinnaiyan AM.

Nat Genet. 2005 Jun;37(6):579-83.

PMID:
15920519
16.

A decade of cancer gene profiling: from molecular portraits to molecular function.

Sara H, Kallioniemi O, Nees M.

Methods Mol Biol. 2010;576:61-87. doi: 10.1007/978-1-59745-545-9_5. Review.

PMID:
19882258
17.

[Gene expression profiling of ER+ breast cancers: to discriminate the poor prognosis tumors or to define the most suitable treatment?].

Chanrion M, Darbon JM.

Bull Cancer. 2008 May;95(5):513-8. doi: 10.1684/bdc.2008.0646. Review. French.

18.

A modular analysis of breast cancer reveals a novel low-grade molecular signature in estrogen receptor-positive tumors.

Yu K, Ganesan K, Miller LD, Tan P.

Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3288-96.

19.

Challenges in projecting clustering results across gene expression-profiling datasets.

Lusa L, McShane LM, Reid JF, De Cecco L, Ambrogi F, Biganzoli E, Gariboldi M, Pierotti MA.

J Natl Cancer Inst. 2007 Nov 21;99(22):1715-23. Epub 2007 Nov 13.

PMID:
18000217
20.

An integrative approach to characterize disease-specific pathways and their coordination: a case study in cancer.

Xu M, Kao MC, Nunez-Iglesias J, Nevins JR, West M, Zhou XJ.

BMC Genomics. 2008;9 Suppl 1:S12. doi: 10.1186/1471-2164-9-S1-S12.

Supplemental Content

Support Center